624 related articles for article (PubMed ID: 28217094)
1.
Watt G; Karl T
Front Pharmacol; 2017; 8():20. PubMed ID: 28217094
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer's disease.
Coles M; Steiner-Lim GZ; Karl T
Front Neurosci; 2022; 16():962922. PubMed ID: 36117622
[TBL] [Abstract][Full Text] [Related]
3. Chronic Treatment with 50 mg/kg Cannabidiol Improves Cognition and Moderately Reduces Aβ40 Levels in 12-Month-Old Male AβPPswe/PS1ΔE9 Transgenic Mice.
Watt G; Shang K; Zieba J; Olaya J; Li H; Garner B; Karl T
J Alzheimers Dis; 2020; 74(3):937-950. PubMed ID: 32116258
[TBL] [Abstract][Full Text] [Related]
4. Understanding the Modulatory Effects of Cannabidiol on Alzheimer's Disease.
Xiong Y; Lim CS
Brain Sci; 2021 Sep; 11(9):. PubMed ID: 34573232
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease.
Karl T; Garner B; Cheng D
Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):142-160. PubMed ID: 27471947
[TBL] [Abstract][Full Text] [Related]
6. Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice.
Cheng D; Spiro AS; Jenner AM; Garner B; Karl T
J Alzheimers Dis; 2014; 42(4):1383-96. PubMed ID: 25024347
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer's Disease.
Hickey JP; Collins AE; Nelson ML; Chen H; Kalisch BE
Curr Issues Mol Biol; 2024 May; 46(5):4379-4402. PubMed ID: 38785534
[TBL] [Abstract][Full Text] [Related]
8. Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice.
Cheng D; Low JK; Logge W; Garner B; Karl T
Psychopharmacology (Berl); 2014 Aug; 231(15):3009-17. PubMed ID: 24577515
[TBL] [Abstract][Full Text] [Related]
9. Chronic cannabidiol (CBD) treatment did not exhibit beneficial effects in 4-month-old male TAU58/2 transgenic mice.
Watt G; Chesworth R; Przybyla M; Ittner A; Garner B; Ittner LM; Karl T
Pharmacol Biochem Behav; 2020 Sep; 196():172970. PubMed ID: 32562718
[TBL] [Abstract][Full Text] [Related]
10. Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease.
Vallée A; Lecarpentier Y; Guillevin R; Vallée JN
Acta Biochim Biophys Sin (Shanghai); 2017 Oct; 49(10):853-866. PubMed ID: 28981597
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke.
Hayakawa K; Mishima K; Fujiwara M
Pharmaceuticals (Basel); 2010 Jul; 3(7):2197-2212. PubMed ID: 27713349
[TBL] [Abstract][Full Text] [Related]
12.
Viana MB; de Aquino PEA; Estadella D; Ribeiro DA; Viana GSB
Med Cannabis Cannabinoids; 2022; 5(1):207-219. PubMed ID: 36467781
[TBL] [Abstract][Full Text] [Related]
13. Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice.
Aso E; Sánchez-Pla A; Vegas-Lozano E; Maldonado R; Ferrer I
J Alzheimers Dis; 2015; 43(3):977-91. PubMed ID: 25125475
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease, aging, and cannabidiol treatment: a promising path to promote brain health and delay aging.
Liu Y
Mol Biol Rep; 2024 Jan; 51(1):121. PubMed ID: 38227160
[TBL] [Abstract][Full Text] [Related]
15. From
Cassano T; Villani R; Pace L; Carbone A; Bukke VN; Orkisz S; Avolio C; Serviddio G
Front Pharmacol; 2020; 11():124. PubMed ID: 32210795
[No Abstract] [Full Text] [Related]
16. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats.
Malone DT; Jongejan D; Taylor DA
Pharmacol Biochem Behav; 2009 Aug; 93(2):91-6. PubMed ID: 19393686
[TBL] [Abstract][Full Text] [Related]
18. Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of
Coles M; Watt G; Kreilaus F; Karl T
Front Pharmacol; 2020; 11():587604. PubMed ID: 33424597
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol for neurodegenerative disorders: A comprehensive review.
Bhunia S; Kolishetti N; Arias AY; Vashist A; Nair M
Front Pharmacol; 2022; 13():989717. PubMed ID: 36386183
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol Reverses Deficits in Hippocampal LTP in a Model of Alzheimer's Disease.
Hughes B; Herron CE
Neurochem Res; 2019 Mar; 44(3):703-713. PubMed ID: 29574668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
